Trials / Completed

CompletedNCT00002043

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: —

Sponsor: Jacobus Pharmaceutical · Industry
Sex: All
Age: 12 Years
Healthy volunteers: Not accepted

Summary

To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3. To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable.

Conditions

Pneumonia, Pneumocystis Carinii
HIV Infections

Interventions

Type	Name	Description
DRUG	Dapsone

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002043. Inclusion in this directory is not an endorsement.